CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issuing a positive opinion. This recommendation is for the approval of sugemalimab, combined with chemotherapy, as a first-line treatment for metastatic non-small cell lung […]
CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of sugemalimab, an innovative anti-PD-L1 monoclonal antibody, for the treatment of metastatic non-small cell lung cancer (NSCLC). This approval positions sugemalimab to be the first such […]
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]
